VYNE Therapeutics Overview
- Year Founded
-
2003
- Status
-
Acquired/Merged
- Employees
-
10
- Latest Deal Type
-
M&A
VYNE Therapeutics General Information
Description
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
Contact Information
Website
www.vynetherapeutics.comCorporate Office
- 685 Route 202/206 North
- Suite 301
- Bridgewater, NJ 08807
- United States
Corporate Office
- 685 Route 202/206 North
- Suite 301
- Bridgewater, NJ 08807
- United States
VYNE Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 27-Jun-2026 | Completed | Generating Revenue | |||
| 7. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 6. PIPE | 01-Nov-2023 | Completed | Generating Revenue | |||
| 5. Secondary Transaction - Open Market | 24-Jul-2018 | Completed | Generating Revenue | |||
| 4. IPO | 25-Jan-2018 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 28-Jul-2017 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 30-Nov-2015 | $45M | $59.3M | Completed | Product Development | |
| 1. Early Stage VC (Series A) | 19-Aug-2013 | $14.3M | $14.3M | Completed | Product Development |
VYNE Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 14,300 | $0.001000 | $80 | $1000 | $1000 | 1x | $1 | 29.01% |
VYNE Therapeutics Comparisons
Industry
Financing
Details
VYNE Therapeutics Competitors (16)
One of VYNE Therapeutics’s 16 competitors is Evoke Pharma, a Formerly VC-backed company based in Solana Beach, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Evoke Pharma | Formerly VC-backed | Solana Beach, CA | ||||
| Intercept Pharmaceuticals | Formerly VC-backed | Morristown, NJ | ||||
| Talphera | Formerly VC-backed | San Mateo, CA | ||||
| Tioga Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA |
VYNE Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
VYNE Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
VYNE Therapeutics Former Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Access Biotechnology | Corporate Venture Capital | Minority | ||
| Acorn Bioventures | Venture Capital | Minority | ||
| Aisling Capital | Venture Capital | Minority | ||
| Bay City Capital | Venture Capital | Minority | ||
| Cormorant Asset Management | PE/Buyout | Minority |
VYNE Therapeutics Acquisitions (2)
VYNE Therapeutics’s most recent deal was a Reverse Merger with Yarrow Bioscience for . The deal was made on 13-Aug-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Yarrow Bioscience | 13-Aug-2026 | Reverse Merger | Drug Discovery | ||
| Foamix Pharmaceuticals | 09-Mar-2020 | Merger/Acquisition | Pharmaceuticals |
VYNE Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
VYNE Therapeutics FAQs
-
When was VYNE Therapeutics founded?
VYNE Therapeutics was founded in 2003.
-
Where is VYNE Therapeutics headquartered?
VYNE Therapeutics is headquartered in Bridgewater, NJ.
-
What is the size of VYNE Therapeutics?
VYNE Therapeutics has 10 total employees.
-
What industry is VYNE Therapeutics in?
VYNE Therapeutics’s primary industry is Drug Discovery.
-
Is VYNE Therapeutics a private or public company?
VYNE Therapeutics is a Private company.
-
What is VYNE Therapeutics’s current revenue?
The current revenue for VYNE Therapeutics is .
-
How much funding has VYNE Therapeutics raised over time?
VYNE Therapeutics has raised $317M.
-
Who are VYNE Therapeutics’s investors?
Access Biotechnology, Acorn Bioventures, Aisling Capital, Bay City Capital, and Cormorant Asset Management are 5 of 20 investors who have invested in VYNE Therapeutics.
-
Who are VYNE Therapeutics’s competitors?
Evoke Pharma, Intercept Pharmaceuticals, Talphera, Tioga Pharmaceuticals, and Amgen are some of the 16 competitors of VYNE Therapeutics.
-
When was VYNE Therapeutics acquired?
VYNE Therapeutics was acquired on 27-Jun-2026.
-
Who acquired VYNE Therapeutics?
VYNE Therapeutics was acquired by Yarrow Bioscience.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
